Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Immunome (IMNM) Research & Development (2023 - 2025)

Immunome (IMNM) has disclosed Research & Development for 3 consecutive years, with $50.8 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Research & Development rose 6.01% year-over-year to $50.8 million, compared with a TTM value of $177.3 million through Dec 2025, up 36.86%, and an annual FY2025 reading of $177.3 million, up 36.86% over the prior year.
  • Research & Development was $50.8 million for Q4 2025 at Immunome, up from $49.2 million in the prior quarter.
  • Across five years, Research & Development topped out at $50.8 million in Q4 2025 and bottomed at $3.8 million in Q3 2023.
  • Average Research & Development over 3 years is $27.5 million, with a median of $33.0 million recorded in 2024.
  • The sharpest move saw Research & Development soared 873.06% in 2024, then grew 6.01% in 2025.
  • Year by year, Research & Development stood at $9.6 million in 2023, then skyrocketed by 396.94% to $47.9 million in 2024, then increased by 6.01% to $50.8 million in 2025.
  • Business Quant data shows Research & Development for IMNM at $50.8 million in Q4 2025, $49.2 million in Q3 2025, and $40.5 million in Q2 2025.